The revocation of a Sigma-Aldrich Cas9 patent could be a sign of things to come in other EPO opposition proceedings, but Europe’s CRISPR IP state of play will remain uncertain for several years
1 Apr
2021
How the EPO’s latest CRISPR revocation affects the Cas9 landscape
